Thank you for writing to us. One of our executive will reach back to you through your submitted medium. In case there’s an urgency, feel free to connect over WhatsApp for faster response.
Prefer calling? Dial +9108042755758 (International callers) or 08042755758 (Indian callers).
COMPOSITION:
Each LuciEntre capsule contains: Entrectinib ……. 100mg
INDICATION:
LuciEntre is a kinase inhibitor indicated for the treatment of:
• Adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
• Adult and pediatric patients 12 years of age and older with solid tumors that:
▪have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion as detected by an FDA-approved test without a known acquired resistance mutation,
▪are metastatic or where surgical resection is likely to result in severe morbidity, and
▪have progressed following treatment or have no satisfactory alternative therapy.
DOSAGE AND USE:
• Recommended Dosage for ROS1-Positive Non-Small Cell Lung Cancer: 600 mg orally once daily.
• Recommended Dosage for NTRK Gene Fusion-Positive Solid Tumors:
▪Adults: 600mg orally once daily.
▪Pediatric Patients 12 Years and Older: Recommended dosage is based on body surface area (BSA) as shown below
□ BSA greater than 1.50 m2: 600 mg once daily.
□ BSA 1.11 to 1.50 m2: 500 mg once daily.
□ BSA 0.91 to 1.10 m2: 400 mg once daily.
Capsules should be swallowed whole & not chewed or crushed.
STORAGE:
in a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
COMPOSITION:
Each film-coated tablet contains Belumosudil mesylate 242.5mg equivalent to Belumosudil ………………………. 200mg.
INDICATION:
LuciBelu is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
DOSAGE AND USE:
Recommended Dosage: 200 mg taken orally once daily with food.
STORAGE:
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
COMPOSITION:
Each film-coated tablet contains Tepotinib hydrochloride hydrate 250mg equivalent to Tepotinib…………………………….225mg.
INDICATION:
LuciTepo is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal epithelial transition (MET) exon 14 skipping alterations.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DOSAGE AND USE:
• Select patients for treatment with LuciTepo on the presence of METex14 skipping.
• Recommended dosage: 450mg orally once daily with food until disease progression or unacceptable toxicity.
STORAGE:
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
COMPOSITION:
Each LuciRepo capsule contains: Repotrectinib ………………………….…… 40mg
INDICATION:
LuciRepo is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
DOSAGE AND USE:
• Select patients for the treatment of locally advanced or metastatic NSCLC based on the presence of ROS1 rearrangement(s) in tumor specimens.
• Recommended Dosage: 160 mg orally once daily for 14 days, then increase to 160 mg twice daily, with or without food.
Capsules should be swallowed whole & not chewed or crushed.
STORAGE:
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
